Technical Analysis for BOLT - Bolt Biotherapeutics, Inc.

Grade Last Price % Change Price Change
D 1.14 2.70% 0.03
BOLT closed up 2.7 percent on Monday, March 18, 2024, on 87 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 27
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish 2.70%
Stochastic Reached Oversold Weakness 2.70%
Lower Bollinger Band Touch Weakness 2.70%
Oversold Stochastic Weakness 2.70%
200 DMA Resistance Bearish 3.64%
Fell Below 50 DMA Bearish 3.64%
Down 3 Days in a Row Weakness 3.64%

   Recent Intraday Alerts

Alert Time
200 DMA Resistance about 12 hours ago
50 DMA Resistance about 12 hours ago
Rose Above Previous Day's High about 12 hours ago
Rose Above 200 DMA about 12 hours ago
Up 5% about 12 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Tumor Pharmaceutical Products Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu

Is BOLT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.03
52 Week Low 0.84
Average Volume 115,662
200-Day Moving Average 1.15
50-Day Moving Average 1.15
20-Day Moving Average 1.20
10-Day Moving Average 1.21
Average True Range 0.08
RSI (14) 46.52
ADX 21.88
+DI 21.36
-DI 20.97
Chandelier Exit (Long, 3 ATRs) 1.15
Chandelier Exit (Short, 3 ATRs) 1.32
Upper Bollinger Bands 1.32
Lower Bollinger Band 1.08
Percent B (%b) 0.24
BandWidth 19.80
MACD Line 0.01
MACD Signal Line 0.03
MACD Histogram -0.0178
Fundamentals Value
Market Cap 43.28 Million
Num Shares 38 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -0.60
Price-to-Sales 5.68
Price-to-Book 0.31
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.24
Resistance 3 (R3) 1.24 1.21 1.23
Resistance 2 (R2) 1.21 1.18 1.21 1.22
Resistance 1 (R1) 1.17 1.16 1.19 1.17 1.22
Pivot Point 1.14 1.14 1.15 1.14 1.14
Support 1 (S1) 1.10 1.11 1.12 1.11 1.06
Support 2 (S2) 1.07 1.09 1.07 1.06
Support 3 (S3) 1.03 1.07 1.05
Support 4 (S4) 1.04